Affordable Access

deepdyve-link
Publisher Website

Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.

Authors
  • Feliubadaló, Lídia1, 2, 3
  • López-Fernández, Adrià4
  • Pineda, Marta1, 2, 3
  • Díez, Orland5, 6
  • Del Valle, Jesús1, 2, 3
  • Gutiérrez-Enríquez, Sara5
  • Teulé, Alex1, 2, 3
  • González, Sara1, 2, 3
  • Stjepanovic, Neda4, 7
  • Salinas, Mónica1, 2, 3
  • Capellá, Gabriel1, 2, 3
  • Brunet, Joan1, 8, 9
  • Lázaro, Conxi1, 2, 3
  • Balmaña, Judith4, 7
  • 1 Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. , (Spain)
  • 2 Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. , (Spain)
  • 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain. , (Spain)
  • 4 High Risk and Familial Cancer, Vall d'Hebron Institute of Oncology, Barcelona.
  • 5 Oncogenetics Group, Vall d'Hebron Institute of Oncology Barcelona, Barcelona, Spain. , (Spain)
  • 6 Molecular and Clinical Genetics Area. Hospital Vall d'Hebron, Universitat Autonòma de Barcelona, Barcelona, Spain. , (Spain)
  • 7 Medical Oncology Department. Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. , (Spain)
  • 8 Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGI, Girona, Spain. , (Spain)
  • 9 Medical Sciences Department, School of Medicine, University of Girona, Girona, Spain. , (Spain)
Type
Published Article
Journal
International Journal of Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
Nov 15, 2019
Volume
145
Issue
10
Pages
2682–2691
Identifiers
DOI: 10.1002/ijc.32304
PMID: 30927264
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Multigene panels provide a powerful tool for analyzing several genes simultaneously. We evaluated the frequency of pathogenic variants (PV) in customized predefined panels according to clinical suspicion by phenotype and compared it to the yield obtained in the analysis of our clinical research gene panel. We also investigated mutational yield of opportunistic testing of BRCA1/2 and mismatch repair (MMR) genes in all patients. A total of 1,205 unrelated probands with clinical suspicion of hereditary cancer were screened for germline mutations using panel testing. Overall, 1,048 females and 157 males were analyzed, mean age at cancer diagnosis was 48; 883 had hereditary breast/ovarian cancer-suspicion, 205 hereditary nonpolyposis colorectal cancer (HNPCC)-suspicion, 73 adenomatous-polyposis-suspicion and 44 with other/multiple clinical criteria. At least one PV was found in 150 probands (12%) analyzed by our customized phenotype-driven panel. Tumoral MMR deficiency predicted for the presence of germline MMR gene mutations in patients with HNPCC-suspicion (46/136 vs. 0/56 in patients with and without MMR deficiency, respectively). Opportunistic testing additionally identified five MSH6, one BRCA1 and one BRCA2 carriers (0.6%). The analysis of the extended 24-gene panel provided 25 additional PVs (2%), including in 4 out of 51 individuals harboring MMR-proficient colorectal tumors (2 CHEK2 and 2 ATM). Phenotype-based panels provide a notable rate of PVs with clinical actionability. Opportunistic testing of MMR and BRCA genes leads to a significant straightforward identification of MSH6, BRCA1 and BRCA2 mutation carriers, and endorses the model of opportunistic testing of genes with clinical utility within a standard genetic counseling framework. © 2019 UICC.

Report this publication

Statistics

Seen <100 times